vs
BLACKBAUD INC（BLKB）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
BLACKBAUD INC的季度营收约是Ultragenyx Pharmaceutical Inc.的1.4倍（$281.1M vs $207.3M），BLACKBAUD INC净利率更高（11.1% vs -62.0%，领先73.1%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 4.2%），BLACKBAUD INC自由现金流更多（$37.0M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs -1.1%）
Blackbaud是全球知名的云服务提供商，专注为非营利组织、基金会、企业、教育机构、医疗机构、宗教团体及个人公益推动者提供技术支持，旗下产品覆盖筹款、网站管理、客户关系管理、数据分析、财务管理、票务系统、教育管理等多元场景。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
BLKB vs RARE — 直观对比
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $281.1M | $207.3M |
| 净利润 | $31.1M | $-128.6M |
| 毛利率 | 59.2% | — |
| 营业利润率 | 18.3% | -54.7% |
| 净利率 | 11.1% | -62.0% |
| 营收同比 | 4.2% | 25.9% |
| 净利润同比 | 620.3% | 3.5% |
| 每股收益（稀释后） | $0.67 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q1 26 | $281.1M | — | ||
| Q4 25 | $295.3M | $207.3M | ||
| Q3 25 | $281.1M | $159.9M | ||
| Q2 25 | $282.0M | $166.5M | ||
| Q1 25 | $269.9M | $139.3M | ||
| Q4 24 | $302.1M | $164.6M | ||
| Q3 24 | $286.6M | $139.5M | ||
| Q2 24 | $287.3M | $147.0M |
| Q1 26 | $31.1M | — | ||
| Q4 25 | $36.7M | $-128.6M | ||
| Q3 25 | $47.5M | $-180.4M | ||
| Q2 25 | $26.5M | $-115.0M | ||
| Q1 25 | $4.3M | $-151.1M | ||
| Q4 24 | $-346.4M | $-133.2M | ||
| Q3 24 | $18.3M | $-133.5M | ||
| Q2 24 | $21.2M | $-131.6M |
| Q1 26 | 59.2% | — | ||
| Q4 25 | 58.3% | — | ||
| Q3 25 | 59.6% | — | ||
| Q2 25 | 59.7% | — | ||
| Q1 25 | 57.5% | — | ||
| Q4 24 | 53.8% | — | ||
| Q3 24 | 54.9% | — | ||
| Q2 24 | 56.0% | — |
| Q1 26 | 18.3% | — | ||
| Q4 25 | 20.0% | -54.7% | ||
| Q3 25 | 19.4% | -106.9% | ||
| Q2 25 | 20.3% | -64.8% | ||
| Q1 25 | 7.3% | -102.6% | ||
| Q4 24 | -121.5% | -74.3% | ||
| Q3 24 | 14.4% | -94.6% | ||
| Q2 24 | 14.4% | -79.1% |
| Q1 26 | 11.1% | — | ||
| Q4 25 | 12.4% | -62.0% | ||
| Q3 25 | 16.9% | -112.8% | ||
| Q2 25 | 9.4% | -69.0% | ||
| Q1 25 | 1.6% | -108.5% | ||
| Q4 24 | -114.6% | -80.9% | ||
| Q3 24 | 6.4% | -95.7% | ||
| Q2 24 | 7.4% | -89.5% |
| Q1 26 | $0.67 | — | ||
| Q4 25 | $0.75 | $-1.28 | ||
| Q3 25 | $0.98 | $-1.81 | ||
| Q2 25 | $0.55 | $-1.17 | ||
| Q1 25 | $0.09 | $-1.57 | ||
| Q4 24 | $-6.82 | $-1.34 | ||
| Q3 24 | $0.35 | $-1.40 | ||
| Q2 24 | $0.41 | $-1.52 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $34.1M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $34.6M | $-80.0M |
| 总资产 | $2.1B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q1 26 | $34.1M | — | ||
| Q4 25 | $38.9M | $421.0M | ||
| Q3 25 | $38.3M | $202.5M | ||
| Q2 25 | $41.6M | $176.3M | ||
| Q1 25 | $37.2M | $127.1M | ||
| Q4 24 | $67.6M | $174.0M | ||
| Q3 24 | $34.6M | $150.6M | ||
| Q2 24 | $30.4M | $480.7M |
| Q1 26 | — | — | ||
| Q4 25 | $1.1B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | $1.0B | — | ||
| Q2 24 | $1.0B | — |
| Q1 26 | $34.6M | — | ||
| Q4 25 | $85.1M | $-80.0M | ||
| Q3 25 | $108.2M | $9.2M | ||
| Q2 25 | $72.7M | $151.3M | ||
| Q1 25 | $17.5M | $144.2M | ||
| Q4 24 | $126.8M | $255.0M | ||
| Q3 24 | $544.8M | $346.8M | ||
| Q2 24 | $577.5M | $432.4M |
| Q1 26 | $2.1B | — | ||
| Q4 25 | $2.4B | $1.5B | ||
| Q3 25 | $2.1B | $1.2B | ||
| Q2 25 | $2.6B | $1.3B | ||
| Q1 25 | $2.1B | $1.3B | ||
| Q4 24 | $2.5B | $1.5B | ||
| Q3 24 | $2.6B | $1.5B | ||
| Q2 24 | $3.0B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | 13.06× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 8.50× | — | ||
| Q3 24 | 1.84× | — | ||
| Q2 24 | 1.78× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $51.5M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $37.0M | $-100.8M |
| 自由现金流率自由现金流/营收 | 13.2% | -48.6% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | 1.65× | — |
| 过去12个月自由现金流最近4个季度 | $294.1M | $-472.0M |
8季度趋势，按日历期对齐
| Q1 26 | $51.5M | — | ||
| Q4 25 | $58.0M | $-99.8M | ||
| Q3 25 | $139.2M | $-91.4M | ||
| Q2 25 | $66.9M | $-108.3M | ||
| Q1 25 | $1.4M | $-166.5M | ||
| Q4 24 | $73.6M | $-79.3M | ||
| Q3 24 | $104.0M | $-67.0M | ||
| Q2 24 | $53.1M | $-77.0M |
| Q1 26 | $37.0M | — | ||
| Q4 25 | $55.0M | $-100.8M | ||
| Q3 25 | $135.7M | $-92.7M | ||
| Q2 25 | $66.3M | $-110.7M | ||
| Q1 25 | $712.0K | $-167.8M | ||
| Q4 24 | $73.4M | $-79.5M | ||
| Q3 24 | $102.9M | $-68.6M | ||
| Q2 24 | $48.0M | $-79.0M |
| Q1 26 | 13.2% | — | ||
| Q4 25 | 18.6% | -48.6% | ||
| Q3 25 | 48.3% | -58.0% | ||
| Q2 25 | 23.5% | -66.5% | ||
| Q1 25 | 0.3% | -120.5% | ||
| Q4 24 | 24.3% | -48.3% | ||
| Q3 24 | 35.9% | -49.2% | ||
| Q2 24 | 16.7% | -53.7% |
| Q1 26 | — | — | ||
| Q4 25 | 1.0% | 0.5% | ||
| Q3 25 | 1.2% | 0.8% | ||
| Q2 25 | 0.2% | 1.5% | ||
| Q1 25 | 0.3% | 1.0% | ||
| Q4 24 | 0.1% | 0.1% | ||
| Q3 24 | 0.4% | 1.2% | ||
| Q2 24 | 1.8% | 1.4% |
| Q1 26 | 1.65× | — | ||
| Q4 25 | 1.58× | — | ||
| Q3 25 | 2.93× | — | ||
| Q2 25 | 2.53× | — | ||
| Q1 25 | 0.32× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 5.69× | — | ||
| Q2 24 | 2.50× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BLKB
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
